Aker Biomarine Antarctic As

Norskhydro Asa

Clavis Pharma Asa

Norsk Hydro, A.s.

The United States Government As Represented by the Department of Veterans Affairs

University of Alberta

Mount Sinai School of Medicine

Clavis Pharma As

Finn Myhren

Nils Hoem

Are Dalen

Marit Liland Sandvold

Bernt B&oslash;rretzen

Ole Henrik Eriksen

Håvard Thøgersen

Kjell Torgeir Stokke

Asgeir Saebo

Anil Rajaram Oroskar

Asha Anil Oroskar

Anantha Krishna Mallia

Tove Jule Evjen

Steinar Hagen

Petter-Arnt Hals

Stefan Hupfeld

James F Holland

Bernt Bo Slashedrretzen

Papasani V Subbaiah

Poorna Yalagala

Lewis R Silverman

Carol E Cass

Sugasini Dhavamani

Leon Tai

James D Young

Andreas Berg Storsve

Armend Håti

Sayeh Ahrabi

Havard Thogersen

The present invention provides improved processes for extracting and preparing lipids from biological sources for use in pharmaceuticals, nutraceuticals and functional foods.

Lipid compositions

The present invention provides compositions comprising phosphatidylcholine derived compounds carrying an omega-3 fatty acid for use in prophylaxis or therapy, particularly when administered systemically. This invention further relates to a modified krill oil composition enriched in LPC-DHA and LPC-EPA, methods of making and methods of using to treat neurological and ocular disorders.

Method of treating eye diseases with krill oil

The present invention provides marine lysophosphatidylcholine compositions for use in pharmaceuticals, nutraceuticals and functional foods, as well as methods for making marine lysophosphatidylcholine compositions.

Lysophosphatidylcholine compositions

The invention provides improved processes for extracting and preparing polar lipids (in particular, desirable phospholipids) from krill and other biological sources. The inventors have discovered processes through which it is possible to extract phospholipids to give high phospholipid content and a reduction of undesired components.

Phospholipid compositions and their preparation

Oral capsules have been dismissed as a dosage form for delivery high dosages of krill phospholipids, but by purifying these to high levels it is indeed possible to use this dosage form to deliver, for example, 700 mg or more phospholipids per capsule.

Capsules containing high doses of krill phospholipids

Current krill oil extracts are liquid at room temperature and include only about 45-55% phospholipids. As the purity of phospholipids increases, the extracts become more viscous, making them difficult to handle and process. The invention mixes these pure materials with viscosity-reducing agents to make them amenable to processes such as encapsulation. Thus the invention retains the useful liquid characteristics of known krill extracts while providing much higher concentrations of phospholipids.

Liquid phospholipid-containing compositions for the preparation of pharmaceuticals

Lipid extraction processes

The present invention relates to certain unsaturated fatty acid derivatives of therapeutically active glucocorticoides-fatty acid esters of glucocorticoids as anti-inflammatory and anti-cancer agents and pharmaceutical formulations containing them.

Fatty acid esters of glucocorticoids as anti-inflammatory and anti-cancer agents

The present invention relates to parenteral formulations for certain long chain saturated and monounsaturated fatty acid derivatives of 1-&#x3b2;-D-arabinofuranosylcytosine (cytarabine). In particular, the present invention relates to a parenteral pharmaceutical composition and a method of the preparation thereof, in order to accommodate therapeutically effective doses of the said derivatives ameliorating compliance in treatment of cancer.

Parenteral formulations of elacytarabine derivatives

This invention provides monoclonal antibodies that recognize hENT1. The invention further provides methods of using such monoclonal antibodies as a therapeutic, diagnostic, and/or prophylactic in disorders associated with aberrant hENT1 expression and/or activity.

Anti-human equilibrative nucleoside transporter 1 (hENT1) antibodies and methods of use thereof

The present invention is directed toward compounds of Formula (I) as follows: wherein, where the crossing dashed line illustrates the bond formed joining Rto the molecule of Formula (I);

Azacytidine analogues and uses thereof

This invention relates to certain unsaturated fatty acid derivatives of therapeutically active 1,3-dioxolane nucleoside analogues and to pharmaceutical formulations containing them. The said derivatives fall within formula (I). Compounds of formula (I) can be used in the treatment of a cancerous disease, including solid tumors and haematological cancers such as leukaemias, lymphomas and multiple myelomas. 

Dioxolane derivates for the treatment of cancer

The properties of biologically active compounds, for example drugs and agrochemicals, which contain in their molecular structure one or more functional groups selected from alcohol, ether, phenyl, amino, amido, thiol, carboxylic acid and carboxylic acid ester groups are modified by replacing one or more of these functional groups by a lipophilic group selected from those of the formula: RCOO&mdash;, RCONH&mdash;, RCOS&mdash;, RCH O&mdash;, RCH NH&mdash;, &mdash;COOCH R, &mdash;CONHCH R and &mdash;SCH R, wherein R is a lipophilic moiety selected from cis-8-heptadecenyl, trans-8-heptadecenyl, cis-10-nonadecenyl and trans-10-nonadecenyl.

Fatty acid derivatives

Growing community of inventors

Porsgrunn, Norway

Finn Myhren